|
Biocon Academy announced a 100% placement success for Batch 6 of the Biocon Ramaiah Certificate Programme in Quality Control Analytical, achieved in a record 2.5 hours.
The placement drive attracted top companies, including Biocon, Biocon Biologics, Syngene, RL Fine Chem, Dr Reddy’s Laboratories, and Baxter. Students have secured roles in quality control, analytical research and development, and product surveillance departments. About 80% of the batch members include are female students.
In addition, Biocon Academy recently concluded the 5th edition of 5-day residential course in ‘Medicinal Chemistry, Drug Discovery & Development India (MCADDI) 2024’, in association with the American Chemical Society, Division of Medicinal Chemistry (ACSMEDI), Pharma Innovation Sourcing Centre LLC USA, International Union of Applied and Pure Chemistry (IUPAC), and ACS Publications.
Bindu Ajit, Programme Dean, Biocon Academy said, “Our rigorous training, including functional visits, hands-on sessions and mock interviews, has broadened their learning horizons and prepared them for corporate life. By unlearning old concepts and embracing new knowledge, they have developed the professional skills and confidence needed in the industry. Congratulations to our students, and all the best for their future endeavours.”
Ramgopal Rao S, senior academic manager and coordinator for Biocon Ramaiah Certificate Program in Quality Control Analytical, Biocon Academy said, “It is wonderful to see all the students from QCA Batch 6 secure placements on the first day in companies such as Baxter, Dr Reddy’s, Biocon, Biocon Biologics, Syngene, and RL Fine Chem, across both Quality Control and Analytical R&D departments.”
Biocon Academy’s tailored curriculum, developed in partnership with Ramaiah Institute, ensures students are equipped with a comprehensive foundation in Quality Control Analytical techniques and receives practical training. Thus, empowering students with the skills that companies in the biotech and pharmaceutical sectors are actively seeking.
Salavadi Easwaran, Academic Dean, Biocon Academy said “MCADDI 2024 provided a platform to participants to interact with leading experts in drug discovery and development, engage in insightful discussions on the latest advancements in medicinal chemistry and a lot more. This unique exposure helps them build a strong foundation for a successful career in the biotech sectors; positions them to meet the evolving demands and contribute meaningfully to global healthcare solutions.”
The programme was attended by approximately 100 participants and led by 15 experts who conducted 32 impactful sessions on lead optimization, molecular modelling, in silico tools for medicinal chemistry, the role of heterocycles in drug design, and structure-based approaches to drug development. Innovative 3D lectures and interactive case studies were the limelight of the course, which gave hands-on experience and a deeper understanding of modern drug discovery to the participants.
|